

SARC Biannual Meeting Agenda

November 15, 2012

8:00 am - 12:00 pm

8:00	Introduction	
	Welcome	Jay Wunder
8:15	Chawla Rosenfeld Developmental Therapeutics	
	SARC Developmental Therapeutics Committee Update	Chand Khanna
	Targeting Vulnerable Metastatic Cells	Chand Khanna
	miRNA and Metastasis	David Kirsch
	Oxidative Stress and Metastasis	Poul Sorensen
	<i>Discussion/Q&A</i>	
9:30	SARC Career Development	
	Career Development 2013 Program	Richard Gorlick
	Adoptive T cell Therapy for Patients with Metastatic Sarcoma	Seth Pollack
	Radiation Induced Sarcoma of the Breast	Keila Torres
	<i>Discussion/Q&A</i>	Richard Gorlick
10:30	Break	
10:45	SARC Clinical Trials	
	Clinical Research Committee Update	Andy Wagner/Bill Tap
	Clinical Trials Update:	Scott Okuno
	SARC012 Phase 2 study of saracatinib in resected recurrent osteosarcoma	Lee Helman
	SARC016 Phase 2 study of bevacizumab & everolimus in unresectable or metastatic MPNST	Lee Helman
	SARC020/EORTC Phase 2b/3 study of trabectedin versus doxorubicin for first-line therapy of metastatic soft tissue sarcoma	James Butrynski
	SARC021 Phase 3 trial of TH-302+doxorubicin versus doxorubicin in advanced/metastatic soft tissue sarcoma	Bill Tap
	SARC022 Phase 2 study of anti-IGF-1R therapy in wild-type and pediatric GIST	Meg von Mehren
11:45	SARC Sarcoma SPORE	
	Summary of the SARC Sarcoma SPORE	Raph Pollock